Early AbobotulinumtoxinA (Dysport®) in Post-Stroke Adult Upper Limb Spasticity: ONTIME Pilot Study

The ONTIME study investigated whether early post-stroke abobotulinumtoxinA injection delays appearance or progression of upper limb spasticity (ULS) symptoms. ONTIME (NCT02321436) was a 28-week, exploratory, double-blind, randomized, placebo-controlled study of abobotulinumtoxinA 500U in patients wi...

Full description

Saved in:
Bibliographic Details
Main Authors: Rosales, Raymond, Balcaitiene, Jovita, Berard, Hugues, Maisonobe, Pascal, Goh, Khean, Kumthornthip, Witsanu, Mazlan, Mazlina, Abdul Latif, Lydia, Delos Santos, Mary, Chotiyarnwong, Chayaporn, Tanvijit, Phakamas, Nuez, Odessa, Kong, Keng
Format: Article
Published: MDPI 2018
Subjects:
Online Access:http://eprints.um.edu.my/20873/
https://doi.org/10.3390/toxins10070253
Tags: Add Tag
No Tags, Be the first to tag this record!
id my.um.eprints.20873
record_format eprints
spelling my.um.eprints.208732021-05-25T03:17:24Z http://eprints.um.edu.my/20873/ Early AbobotulinumtoxinA (Dysport®) in Post-Stroke Adult Upper Limb Spasticity: ONTIME Pilot Study Rosales, Raymond Balcaitiene, Jovita Berard, Hugues Maisonobe, Pascal Goh, Khean Kumthornthip, Witsanu Mazlan, Mazlina Abdul Latif, Lydia Delos Santos, Mary Chotiyarnwong, Chayaporn Tanvijit, Phakamas Nuez, Odessa Kong, Keng R Medicine The ONTIME study investigated whether early post-stroke abobotulinumtoxinA injection delays appearance or progression of upper limb spasticity (ULS) symptoms. ONTIME (NCT02321436) was a 28-week, exploratory, double-blind, randomized, placebo-controlled study of abobotulinumtoxinA 500U in patients with ULS (Modified Ashworth Scale [MAS] score ≥ 2) 2–12 weeks post-stroke. Patients were either symptomatic or asymptomatic (only increased MAS) at baseline. Primary efficacy outcome measure: time between injection and visit at which re-injection criteria were met (MAS ≥ 2 and ≥1, sign of symptomatic spasticity: pain, involuntary movements, impaired active or passive function). Forty-two patients were randomized (abobotulinumtoxinA 500U: n = 28; placebo: n = 14) with median 5.86 weeks since stroke. Median time to reach re-injection criteria was significantly longer for abobotulinumtoxinA (156 days) than placebo (32 days; log-rank: p = 0.0176; Wilcoxon: p = 0.0480). Eleven (39.3%) patients receiving abobotulinumtoxinA did not require re-injection for ≥28 weeks versus two (14.3%) in placebo group. In this exploratory study, early abobotulinumtoxinA treatment significantly delayed time to reach re-injection criteria compared with placebo in patients with post-stroke ULS. These findings suggest an optimal time for post-stroke spasticity management and help determine the design and sample sizes for larger confirmatory studies. MDPI 2018 Article PeerReviewed Rosales, Raymond and Balcaitiene, Jovita and Berard, Hugues and Maisonobe, Pascal and Goh, Khean and Kumthornthip, Witsanu and Mazlan, Mazlina and Abdul Latif, Lydia and Delos Santos, Mary and Chotiyarnwong, Chayaporn and Tanvijit, Phakamas and Nuez, Odessa and Kong, Keng (2018) Early AbobotulinumtoxinA (Dysport®) in Post-Stroke Adult Upper Limb Spasticity: ONTIME Pilot Study. Toxins, 10 (7). p. 253. ISSN 2072-6651 https://doi.org/10.3390/toxins10070253 doi:10.3390/toxins10070253
institution Universiti Malaya
building UM Library
collection Institutional Repository
continent Asia
country Malaysia
content_provider Universiti Malaya
content_source UM Research Repository
url_provider http://eprints.um.edu.my/
topic R Medicine
spellingShingle R Medicine
Rosales, Raymond
Balcaitiene, Jovita
Berard, Hugues
Maisonobe, Pascal
Goh, Khean
Kumthornthip, Witsanu
Mazlan, Mazlina
Abdul Latif, Lydia
Delos Santos, Mary
Chotiyarnwong, Chayaporn
Tanvijit, Phakamas
Nuez, Odessa
Kong, Keng
Early AbobotulinumtoxinA (Dysport®) in Post-Stroke Adult Upper Limb Spasticity: ONTIME Pilot Study
description The ONTIME study investigated whether early post-stroke abobotulinumtoxinA injection delays appearance or progression of upper limb spasticity (ULS) symptoms. ONTIME (NCT02321436) was a 28-week, exploratory, double-blind, randomized, placebo-controlled study of abobotulinumtoxinA 500U in patients with ULS (Modified Ashworth Scale [MAS] score ≥ 2) 2–12 weeks post-stroke. Patients were either symptomatic or asymptomatic (only increased MAS) at baseline. Primary efficacy outcome measure: time between injection and visit at which re-injection criteria were met (MAS ≥ 2 and ≥1, sign of symptomatic spasticity: pain, involuntary movements, impaired active or passive function). Forty-two patients were randomized (abobotulinumtoxinA 500U: n = 28; placebo: n = 14) with median 5.86 weeks since stroke. Median time to reach re-injection criteria was significantly longer for abobotulinumtoxinA (156 days) than placebo (32 days; log-rank: p = 0.0176; Wilcoxon: p = 0.0480). Eleven (39.3%) patients receiving abobotulinumtoxinA did not require re-injection for ≥28 weeks versus two (14.3%) in placebo group. In this exploratory study, early abobotulinumtoxinA treatment significantly delayed time to reach re-injection criteria compared with placebo in patients with post-stroke ULS. These findings suggest an optimal time for post-stroke spasticity management and help determine the design and sample sizes for larger confirmatory studies.
format Article
author Rosales, Raymond
Balcaitiene, Jovita
Berard, Hugues
Maisonobe, Pascal
Goh, Khean
Kumthornthip, Witsanu
Mazlan, Mazlina
Abdul Latif, Lydia
Delos Santos, Mary
Chotiyarnwong, Chayaporn
Tanvijit, Phakamas
Nuez, Odessa
Kong, Keng
author_facet Rosales, Raymond
Balcaitiene, Jovita
Berard, Hugues
Maisonobe, Pascal
Goh, Khean
Kumthornthip, Witsanu
Mazlan, Mazlina
Abdul Latif, Lydia
Delos Santos, Mary
Chotiyarnwong, Chayaporn
Tanvijit, Phakamas
Nuez, Odessa
Kong, Keng
author_sort Rosales, Raymond
title Early AbobotulinumtoxinA (Dysport®) in Post-Stroke Adult Upper Limb Spasticity: ONTIME Pilot Study
title_short Early AbobotulinumtoxinA (Dysport®) in Post-Stroke Adult Upper Limb Spasticity: ONTIME Pilot Study
title_full Early AbobotulinumtoxinA (Dysport®) in Post-Stroke Adult Upper Limb Spasticity: ONTIME Pilot Study
title_fullStr Early AbobotulinumtoxinA (Dysport®) in Post-Stroke Adult Upper Limb Spasticity: ONTIME Pilot Study
title_full_unstemmed Early AbobotulinumtoxinA (Dysport®) in Post-Stroke Adult Upper Limb Spasticity: ONTIME Pilot Study
title_sort early abobotulinumtoxina (dysport®) in post-stroke adult upper limb spasticity: ontime pilot study
publisher MDPI
publishDate 2018
url http://eprints.um.edu.my/20873/
https://doi.org/10.3390/toxins10070253
_version_ 1702170271347113984
score 13.209306